Sarepta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Study of Eteplirsen in DMD Patients
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT02255552
- Locations
- 🇺🇸
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)
- Conditions
- Limb-Girdle Muscular Dystrophy, Type 2D
- Interventions
- Genetic: SRP-9004
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01976091
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
- Conditions
- Ebola Hemorrhagic Fever
- Interventions
- Other: Normal Saline Solution (NSS)
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Registration Number
- NCT01593072
- Locations
- 🇺🇸
Quintiles Phase I Services, Overland Park, Kansas, United States
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01566877
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: AVI-4658 (Eteplirsen)
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01540409
- Locations
- 🇺🇸
Miller Children's Hospital, Long Beach, California, United States
🇺🇸Washington University Medical School, Saint Louis, Missouri, United States
🇺🇸Summerwood Pediatrics/Infusacare Medical Services, Liverpool, New York, United States
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: AVI-4658 (Eteplirsen)Other: Placebo
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01396239
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Safety Study of Single Administration Intravenous Treatment for Influenza
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01375985
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01353040
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01353027
- Locations
- 🇺🇸
New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: AVI-4658 for Injection
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00844597
- Locations
- 🇬🇧
Great Ormond Street Hospital, London, England, United Kingdom
🇬🇧Royal Victoria Infirmary, Newcastle Upon Tyne, England, United Kingdom